SCHEMBL29936309

CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)[C@@H](C)O)C(C)C)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 1)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	20/20	0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29641072	0.97	GLP1R (0.65)	GLP1R
SCHEMBL30587681	0.90	GLP1R (0.72)	GLP1R
SCHEMBL30592733	0.90	GLP1R (0.55)	GLP1R
SCHEMBL31366714	0.90	GLP1R (0.62)	GLP1R
SCHEMBL30451312	0.89	C5AR1 (0.70)	GLP1R
SCHEMBL30607486	0.89	IL23R (0.64)	GLP1R
SCHEMBL30216755	0.89	GLP1R (0.72)	GLP1R
SCHEMBL30536323	0.89	GLP1R (0.65)	GLP1R
SCHEMBL31688323	0.89	GLP1R (0.66)	GLP1R
SCHEMBL30906448	0.88	GLP1R (0.75)	GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250319152-A1	METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING	STEALTH BIOTHERAPEUTICS INC. (US)	2025-10-16	—	—	US	disclosed
US-12337023-B2	Methods and compositions for the prevention and treatment of disease	STEALTH BIOTHERAPEUTICS INC. (US)	2025-06-24	—	—	US	disclosed
US-20230043587-A1	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE	STEALTH BIOTHERAPEUTICS INC. (US)	2023-02-09	—	—	US	disclosed
US-20220296672-A1	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY	STEALTH BIOTHERAPEUTICS INC. (US)	2022-09-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230043587-A1	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE	COL2A1, ALPI, COL14A1	GLP1R 1920/4885
US-12337023-B2	Methods and compositions for the prevention and treatment of disease	COL2A1, ALPI, COL14A1	GLP1R 1920/4885
US-20220296672-A1	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY	NGF, GAP43, PRPH	GLP1R 523/4885
US-20250319152-A1	METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING	ARG2, TNNT2, MYLK2	GLP1R 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.